Literature DB >> 3119552

Comparative in-vitro activity of Ro 23-6240, a new trifluorinated quinolone.

L Verbist1.   

Abstract

The in-vitro activity of Ro 23-6240, a new quinolone, was tested in comparison with that of other quinolones against 486 recent clinical isolates. Ro 23-6240 displayed the typical features of the new quinolones: highest activity against Gram-negative bacilli, MBCs close to the MICs, minimum inoculum effect and rapid killing. Against Gram-negative organisms (Enterobacteriaceae, non-fermenters, Haemophilus influenzae and gonococci) the activity of Ro 23-6240 was between that of ofloxacin and norfloxacin; against staphylococci its activity was between that of ciprofloxacin and ofloxacin, and against streptococci it was similar to that of norfloxacin.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3119552     DOI: 10.1093/jac/20.3.363

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

1.  Influence of sex on the pharmacokinetic interaction of fleroxacin and ciprofloxacin with caffeine.

Authors:  Myo-Kyoung Kim; Charles Nightingale; David Nicolau
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Steady-state pharmacokinetics of fleroxacin in patients with skin and skin structure infections.

Authors:  K Heim-Duthoy; G Peltier; W Awni
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

Review 3.  Fleroxacin clinical pharmacokinetics.

Authors:  A E Stuck; D K Kim; F J Frey
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

4.  Fleroxacin resistance in Escherichia coli.

Authors:  J S Chapman; A Bertasso; N H Georgopapadakou
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

5.  Activity of fleroxacin alone and in combination with clindamycin or metronidazole in experimental intra-abdominal abscesses.

Authors:  A Pefanis; C Thauvin-Eliopoulos; J Holden; G M Eliopoulos; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

6.  Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens.

Authors:  A C Panneton; M G Bergeron; M LeBel
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

Review 7.  Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.

Authors:  J A Balfour; P A Todd; D H Peters
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

Review 8.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

Review 9.  Developments in quinolones. Bacteriology, pharmacokinetics and initial clinical experience of several investigational quinolone derivatives.

Authors:  R Janknegt; Y A Hekster
Journal:  Pharm Weekbl Sci       Date:  1989-04-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.